Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

Benzinga · 2d ago
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.